Cargando…

The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry

Background: There is a paucity of data on ethnic disparities in patients with the classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs): polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF). Methods: This study analysed the demographic dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Varghese, Chris, Immanuel, Tracey, Ruskova, Anna, Theakston, Edward, Kalev-Zylinska, Maggie L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167767/
https://www.ncbi.nlm.nih.gov/pubmed/33919650
http://dx.doi.org/10.3390/curroncol28020146
_version_ 1783701758376148992
author Varghese, Chris
Immanuel, Tracey
Ruskova, Anna
Theakston, Edward
Kalev-Zylinska, Maggie L.
author_facet Varghese, Chris
Immanuel, Tracey
Ruskova, Anna
Theakston, Edward
Kalev-Zylinska, Maggie L.
author_sort Varghese, Chris
collection PubMed
description Background: There is a paucity of data on ethnic disparities in patients with the classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs): polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF). Methods: This study analysed the demographic data for PV, ET and PMF collected by the New Zealand Cancer Registry (NZCR) between 2010 and 2017. Results: We found that the NZCR capture rates were lower than average international incidence rates for PV and ET, but higher for PMF (0.76, 0.99 and 0.82 per 100,000, respectively). PV patients were older and had worse outcomes than expected, which suggests these patients were reported to the registry at an advanced stage of their disease. Polynesian patients with all MPN subtypes, PV, ET and PMF, were younger than their European counterparts both at the time of diagnosis and death (p < 0.001). Male gender was an independent risk factor for mortality from PV and PMF (hazard ratios (HR) of 1.43 and 1.81, respectively; p < 0.05), and Māori ethnicity was an independent risk factor for mortality from PMF (HR: 2.94; p = 0.006). Conclusions: New Zealand Polynesian patients may have increased genetic predisposition to MPN, thus we advocate for modern genetic testing in this ethnic group to identify the cause. Further work is also required to identify modifiable risk factors for mortality in MPN, in particular those associated with male gender and Māori ethnicity; the results may benefit all patients with MPN.
format Online
Article
Text
id pubmed-8167767
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81677672021-06-02 The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry Varghese, Chris Immanuel, Tracey Ruskova, Anna Theakston, Edward Kalev-Zylinska, Maggie L. Curr Oncol Article Background: There is a paucity of data on ethnic disparities in patients with the classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs): polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF). Methods: This study analysed the demographic data for PV, ET and PMF collected by the New Zealand Cancer Registry (NZCR) between 2010 and 2017. Results: We found that the NZCR capture rates were lower than average international incidence rates for PV and ET, but higher for PMF (0.76, 0.99 and 0.82 per 100,000, respectively). PV patients were older and had worse outcomes than expected, which suggests these patients were reported to the registry at an advanced stage of their disease. Polynesian patients with all MPN subtypes, PV, ET and PMF, were younger than their European counterparts both at the time of diagnosis and death (p < 0.001). Male gender was an independent risk factor for mortality from PV and PMF (hazard ratios (HR) of 1.43 and 1.81, respectively; p < 0.05), and Māori ethnicity was an independent risk factor for mortality from PMF (HR: 2.94; p = 0.006). Conclusions: New Zealand Polynesian patients may have increased genetic predisposition to MPN, thus we advocate for modern genetic testing in this ethnic group to identify the cause. Further work is also required to identify modifiable risk factors for mortality in MPN, in particular those associated with male gender and Māori ethnicity; the results may benefit all patients with MPN. MDPI 2021-04-18 /pmc/articles/PMC8167767/ /pubmed/33919650 http://dx.doi.org/10.3390/curroncol28020146 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Varghese, Chris
Immanuel, Tracey
Ruskova, Anna
Theakston, Edward
Kalev-Zylinska, Maggie L.
The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry
title The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry
title_full The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry
title_fullStr The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry
title_full_unstemmed The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry
title_short The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry
title_sort epidemiology of myeloproliferative neoplasms in new zealand between 2010 and 2017: insights from the new zealand cancer registry
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167767/
https://www.ncbi.nlm.nih.gov/pubmed/33919650
http://dx.doi.org/10.3390/curroncol28020146
work_keys_str_mv AT varghesechris theepidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry
AT immanueltracey theepidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry
AT ruskovaanna theepidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry
AT theakstonedward theepidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry
AT kalevzylinskamaggiel theepidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry
AT varghesechris epidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry
AT immanueltracey epidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry
AT ruskovaanna epidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry
AT theakstonedward epidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry
AT kalevzylinskamaggiel epidemiologyofmyeloproliferativeneoplasmsinnewzealandbetween2010and2017insightsfromthenewzealandcancerregistry